One of the major tools to evaluate this type of pathology is the neuroendocrine markers as chromogranin A, serotonin, urinary 5-hydroxy indolacetic acid, and neuron specific enolase.
Revista Romana de Medicina de Laborator
They change related to the disease progression, regardless therapy. Some of the drugs that are used for NETs as somatostatin analogs for example octreotide might interfere with glucose metabolism. We analyzed in a retrospective study of 2 years neuroendocrine cancer medicine dynamic of the NET markers and the glycemia profile. Material and Methods. All the patients had at least one assay per year. Neuroendocrine cancer medicine dose of octreotide varied from 20 to 50 mg, monthly.
The fasting glucose insignificantly changed from baseline after 2 years. No new case of diabetes was registered.
Neuroendocrine tumours (NETs): symptoms, diagnosis and treatment
One case of known diabetes needed insulin but interferon therapy was also added during this time period. The chromogranin A had sustained high values for all the 9 cases, marking the disease progression. The neuron specific enolase significantly increased, and the serum serotonin as well as the 5HIIA was much higher in 2 neuroendocrine cancer medicine with aggressive carcinoid symptoms.
The NET markers and the glucose metabolism are most useful tools in the management of NETs, yet they are not correlated. Neuroendocrine tumors.
NEUROENDOCRINE TUMORS: CHOOSING APPROPRIATE IMAGING METHODS | The Medical-Surgical Journal
Endocr Relat Cancer. DOI: Oberndorfer S.
Karzinoide tumoren des dunndarms. Frank Z Pathol. Carcinoid Tumors. Bellizzi AM. Assigning site of origin in metastatic neuroendocrine neoplasms: a clinically significant application of diagnosis immunohistochemistry.
Adv Anat Pathol. Chromogranins A B C: widespread consitituents of secretory vesicles. Ann N Y Acad Sci.
Chromogranin A neuron specific enolase carcinoembryonic antigen and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. CO; 8. Regul Pept.
The poor prognosis factors in G2 neuroendocrine neuroendocrine cancer medicine. Rom J Morphol Embryol.
NEUROENDOCRINE TUMORS: CHOOSING APPROPRIATE IMAGING METHODS
The dedifferentiation neuroendocrine cancer medicine neuroendocrine tumor metastases: myth or reality? Octreotide for the treatment of hypoglycemia after insulin glargine overdose. J Emerg Med. Biochemical testing for neuroendocrine tumors. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors.
- This article provides an overview of the current state of the imaging modalities used for primary tumor visualization, staging and follow-up.
- Papilloma intraduttale
- One of the major tools to evaluate this type of pathology is the neuroendocrine markers as chromogranin A, serotonin, urinary 5-hydroxy indolacetic acid, and neuron specific enolase.
Endocrinol Metab Clin North Am ;40 1 Well-differentiated neuroendocrine tumor and osteoporosis: incidental finding? Treatment of malignant midgut carcinoid tumours with a long-acting somatostatin analogue octreotide.
Long-term clinical outcome of somatostatin analogues for treatment of pregressive metastatic well-differentiated entero-pancreatic endocrine carcinoma. Ann Oncol. Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced neuroendocrine cancer medicine endocrine carcinoma.